◼ Archived
Business
Novo's next-generation obesity drug shows 25% weight loss in women in late-stage analysis
Novo's next-generation obesity drug CagriSema showed 25 percent weight loss in women in late-stage analysis.
Cagrisema
2 trends tracked about this subject — the full history, oldest to newest below.
◼ Archived
Business
Novo says CagriSema shows greater weight loss than Lilly rival in diabetes patients
6 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.